Market Cap (In SEK)
228.64 Million
Revenue (In SEK)
-
Net Income (In SEK)
-44.05 Million
Avg. Volume
652.85 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.203-0.932
- PE
- -
- EPS
- -
- Beta Value
- 1.06
- ISIN
- SE0009664154
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Anders Haegerstrand M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.annexinpharma.com/sv
- Ipo Date
- 2017-04-19
- Details
- Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.
More Stocks
-
ALLR
-
TRAD
-
PREC
-
ATLX
-
WALL-BWallenstam AB (publ)
WALL-B
-
SAI
-
SYNACTSynAct Pharma AB
SYNACT
-
RAIL